John Whelan: US drug price shake-up threatens EU medicine access
Pharma companies, many of which have operations in Ireland, may delay product launches here to avoid price erosion in larger markets. File picture: Dan Linehan
US president Donald Trump’s “most favoured nation” medicines strategy for the US could force up prices in Europe and make medicines scarcer in smaller countries like Ireland.
In a direct letter to 17 top pharmaceutical manufacturers in late July he warned they had two months to align United States prices for brand-name drugs with the lowest offered in other developed nations, so-called most favoured nation (MFN) pricing.
